Related Experiment Video

Updated: May 15, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies

Ning Shao1, Wen Yu Jiang, Di Qiao

  • 1Department of Urology, Jiangsu Province Geriatric Hospital, Nanjing, China.

Cancer Biomarkers : Section a of Disease Markers
|January 17, 2013
PubMed
Abstract

Insights

This meta-analysis found that specific single nucleotide polymorphisms (SNPs) in the DNA repair gene XRCC4, particularly rs28360071, are significantly associated with increased cancer risk. Further research is needed to understand the underlying biological mechanisms.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • DNA repair genes, including XRCC4, are increasingly recognized for their potential role in cancer susceptibility.
  • Previous studies on single nucleotide polymorphisms (SNPs) in XRCC4 and their association with cancer risk have yielded conflicting results.
  • An updated meta-analysis is necessary to clarify the relationship between XRCC4 genetic variations and cancer risk.

Purpose of the Study:

  • To conduct an updated meta-analysis to precisely estimate the association between XRCC4 polymorphisms and cancer risk.
  • To investigate specific SNPs within the XRCC4 gene and their correlation with the risk of developing various cancers.

Main Methods:

  • A comprehensive literature search was performed to identify all relevant studies examining XRCC4 polymorphisms and cancer risk.
  • Odds ratios (ORs) with 95% confidence intervals (CIs) were utilized to quantify the strength of the observed associations.
  • Meta-analysis techniques were applied to synthesize data from 31 eligible studies involving 8 different SNPs in the XRCC4 gene.

Main Results:

  • The meta-analysis identified significant associations between two XRCC4 polymorphisms, rs28360071 and rs2075686, and overall cancer risk.
  • Subgroup analyses revealed significant associations for specific SNPs in particular cancer types: rs28360071 with prostate cancer, rs6869366 with lung cancer, and rs1805377 with bladder cancer.

Conclusions:

  • This meta-analysis provides evidence supporting the association between specific single nucleotide polymorphisms (SNPs) in the XRCC4 gene and cancer risk.
  • The rs28360071 polymorphism in XRCC4 showed a significant association with overall cancer risk.
  • Further investigation into the molecular mechanisms underlying the biological functions of XRCC4 SNPs in cancer development is warranted.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...